These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

447 related items for PubMed ID: 24582176

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis].
    Varela CU, Prieto-Rayo JC.
    Rev Med Chil; 2014 Dec; 142(12):1565-74. PubMed ID: 25693439
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN.
    Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
    [Abstract] [Full Text] [Related]

  • 6. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
    Elmholdt TR, Pedersen M, Jørgensen B, Søndergaard K, Jensen JD, Ramsing M, Olesen AB.
    Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Nephrogenic systemic fibrosis.
    Weinreb JC, Kuo PH.
    Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
    [Abstract] [Full Text] [Related]

  • 9. Nephrogenic systemic fibrosis and gadolinium-based contrast agents.
    Abu-Alfa AK.
    Adv Chronic Kidney Dis; 2011 May; 18(3):188-98. PubMed ID: 21531325
    [Abstract] [Full Text] [Related]

  • 10. Nephrogenic systemic fibrosis: clinical picture and treatment.
    Marckmann P, Skov L.
    Radiol Clin North Am; 2009 Sep; 47(5):833-40, vi. PubMed ID: 19744598
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure.
    Bernstein EJ, Schmidt-Lauber C, Kay J.
    Best Pract Res Clin Rheumatol; 2012 Aug; 26(4):489-503. PubMed ID: 23040363
    [Abstract] [Full Text] [Related]

  • 13. Guideline to use gadolinium-based contrast agents at Kyoto University Hospital.
    Miki Y, Isoda H, Togashi K.
    J Magn Reson Imaging; 2009 Dec; 30(6):1364-5. PubMed ID: 19937936
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
    Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH.
    Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
    Woolen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS.
    JAMA Intern Med; 2020 Feb 01; 180(2):223-230. PubMed ID: 31816007
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents.
    Kitajima K, Maeda T, Watanabe S, Ueno Y, Sugimura K.
    Int J Urol; 2012 Sep 01; 19(9):806-11. PubMed ID: 22571387
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.